On 10 May 2014
Dr Datsons Labs announced that a meeting of the Board of Directors of the Company will be held on 10 May 2014, to transact the following:Increase in authorize capital of the Company from Rs 50 crore to Rs 80 crore subject to the approval of the Members of the Company.
To consider the Company's fund raising program by way of issue of equity shares on preferential basis to Non Promoters up to US$ 25.00 million, as per the Applicable provisions of the companies Act 2013 and SEBI Regulations, subject to the approval of the Members of the Company.
To consider issue of Foreign Currency convertible Bonds [FCCBs], American Depository Receipts [ADR] and Global Depository Receipts [GDR] upto US$ 25.00 million as per the Applicable provisions of the companies Act 2013 and SEBI Regulations, subject to the approval of the Members of the Company.
Powered by Capital Market - Live News